Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Baxter
QuintilesIMS
Chubb
US Department of Justice
Colorcon
Cerilliant
McKinsey
Merck
Mallinckrodt

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,630,162

« Back to Dashboard

Which drugs does patent 6,630,162 protect, and when does it expire?

Patent 6,630,162 protects DETROL LA and is included in one NDA.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 6,630,162
Title: Pharmaceutical formulation and its use
Abstract:The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
Inventor(s): Nilvebrant; Lisbeth (Bromma, SE), Hallen; Bengt (Sollentuna, SE), Olsson; Birgitta (Stenhamra, SE), Strombom; Jan (Vattholm, SE), Gren; Torkek (Kalamazoo, MI), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/708,428
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 6,630,162

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,630,162

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0000782Mar 09, 2000

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Dow
Chubb
AstraZeneca
Citi
Daiichi Sankyo
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot